Clinical Trial Search Results

This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive Cancer Center's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

This phase II trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and nivolumab may work better in treating patients with TFE/translocation renal cell carcinoma compared to standard treatment, including surgery, chemotherapy, or immunotherapy.

Parts 1 and 2 The primary purpose of this study is to understand the safety of NL-201 when given intravenously as monotherapy in patients with advanced cancer to evaluate tolerability and to identify a recommended dose and schedule for further testing.

This phase II trial investigates how well pamiparib and temozolomide work in treating patients with hereditary leiomyomatosis and renal cell (kidney) cancer. Poly adenosine diphosphate-ribose polymerase (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as pamiparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pamiparib and temozolomide may help treat patients with hereditary leiomyomatosis and renal cell cancer.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive Cancer Center's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive Cancer Center's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive Cancer Center's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.

PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clear cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma and urothelial tumors. This study contains two parts, single agent dose escalation (Part 1A), dose finding of PF 06940434 in combination with anti-PD-1 (Part 1B) and dose expansion (Part 2). Part 2 Dose Combination Expansion will enroll participants into 2 cohorts at doses determined from Part 1B in order to further evaluate the safety of PF-06940434 in combination with anti-PD-1.

This will be a Phase 1b, first in human, open-label, dose escalation and expansion study of MT-5111 (a recombinant fusion protein) given as monotherapy in subjects with HER2-positive solid tumors

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types:

The purpose of this research study is to find out if the study drug, ALT-803, plus BCG can stop the growth of tumor in patients with non-muscle invasive bladder cancer whose tumor persisted after treatment with BCG. The sponsor also wish to collect some other information that will help them to improve the way study drug is given to patients.

In this research study, ALT-803 will be tested with BCG.

Patient will have a complete physical exam and vital signs including height, weight, heart and breathing rate, blood pressure and temperature will be checked. About two teaspoons of blood will be collected for testing the functions of patient's kidneys, liver and other organs and for blood cell counts. We will also collect urine for routine urine tests. An electrocardiogram (EKG) will be run to test electrical activity of patient's heart. The patient's lung functions will be examined if it is indicated, and will need to have a biopsy of patient's tumor tissue within 6 weeks of study entry to check the status of the disease. We also need to collect some tissue from these biopsies. The tissue may be analyzed for genes, gene products, proteins, or makers involved in cancer, interleukin response or cell death. The tissue from patient's biopsies that are collected for testing will be analyzed and stored for possible future analysis. Results from these screening tests will be used by the study doctor to find out if the patient qualifies for the research study. If the patient is a woman who can have children, we will collect another teaspoon of blood for a pregnancy test. The study doctor or study staff will tell the patient if the pregnancy test results are positive. The results of the pregnancy test must be negative in order for you to be in the study. We will enroll the patient and schedule their visits to receive the study treatment within 14 days. If the screening tests show that the patient is not eligible to continue in the research study, then the patient may not take part.

Patient's participation in the study will include one cycle of study treatment consisting of six weekly doses of BCG plus ALT-803 study drug and every 3 months visits to evaluate their response to the study treatment. Participants will receive 4 cycles of 3 weekly doses of BCG plus ALT-803 every 3 months if there is no tumor growth. Participants will receive another cycle of study treatment consisting of six weekly doses of BCG plus ALT-803 if there is a decrease in amount of cancer (residual tumor) at 3 months, followed by 4 cycles of 3 weekly doses of BCG plus ALT-803 every 3 months if there is no tumor growth in follow ups. If there is no decrease in the amount of cancer in after one cycle of treatment (6 weeks), patients will not receive more doses of study treatment.

Patient will be closely monitored during the entire treatment period. This study will last as long as patient does not have unacceptable side effects. After the patient completes the study treatment period, if they received at least one dose of study treatment, we will continue to monitor and follow the patients disease and health status every 3 months during years 1 and 2 by scheduled office visits